drugset / Trial / NCT06060405
Durvalumab and Oleclumab in Resectable PDAC
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-site Canadian, window of opportunity study to evaluate the immune activity of durvalumab and oleclumab in resectable pancreatic ductal adenocarcinoma (PDAC) when given prior to surgery.
Timeline
- Start
- 2023-11-29
- Primary completion
- 2026-10-30
- Completion
- 2026-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |
| Subject | Oleclumab | Monoclonal antibody | 3000 mg | — |